- Home
- EXEL vs BBIO Comparison
EXEL vs BBIO Comparison
Compare EXEL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- BBIO
- Stock Information
- Founded
- EXEL 1994
- BBIO 2015
- Country
- EXEL United States
- BBIO United States
- Employees
- EXEL N/A
- BBIO N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- EXEL Health Care
- BBIO Health Care
- Exchange
- EXEL Nasdaq
- BBIO Nasdaq
- Market Cap
- EXEL 11.1B
- BBIO 10.4B
- IPO Year
- EXEL 2000
- BBIO 2019
- Fundamental
- Price
- EXEL $42.52
- BBIO $66.36
- Analyst Decision
- EXEL Buy
- BBIO Strong Buy
- Analyst Count
- EXEL 24
- BBIO 19
- Target Price
- EXEL $44.73
- BBIO $74.79
- AVG Volume (30 Days)
- EXEL 3.3M
- BBIO 2.7M
- Earning Date
- EXEL 11-04-2025
- BBIO 10-29-2025
- Dividend Yield
- EXEL N/A
- BBIO N/A
- EPS Growth
- EXEL 53.55
- BBIO N/A
- EPS
- EXEL 2.38
- BBIO N/A
- Revenue
- EXEL $2,288,218,000.00
- BBIO $353,780,000.00
- Revenue This Year
- EXEL $9.14
- BBIO $123.32
- Revenue Next Year
- EXEL $12.51
- BBIO $73.46
- P/E Ratio
- EXEL $17.53
- BBIO N/A
- Revenue Growth
- EXEL 9.93
- BBIO 62.46
- 52 Week Low
- EXEL $31.90
- BBIO $21.72
- 52 Week High
- EXEL $49.62
- BBIO $69.48
- Technical
- Relative Strength Index (RSI)
- EXEL 60.26
- BBIO 65.07
- Support Level
- EXEL $41.23
- BBIO $63.91
- Resistance Level
- EXEL $43.72
- BBIO $67.71
- Average True Range (ATR)
- EXEL 1.47
- BBIO 3.09
- MACD
- EXEL 0.34
- BBIO 0.14
- Stochastic Oscillator
- EXEL 83.81
- BBIO 63.62
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.